Table 3

Outcomes between baseline and 12 months by subgroups of participants enrolled into the trial if they had central obesity and/or elevated HbA1c levels

BaselineFollow-upAdjusted difference (95% CI)P value
Inclusion based on central obesity
 Weight (kg)Intervention83.1 (12.8)81.4 (13.0)−1.1 (−1.7 to −0.5)<0.0014
Control81.8 (12.9)81.4 (13.6)
 Waist circumference (cm)Intervention106.6 (7.5)103.1 (9.1)−1.8 (−2.4 to −1.3)<0.001
Control106.6 (7.7)105.1 (9.1)
 SBP (mm Hg)Intervention131.0 (16.6)130.6 (16.8)−0.9 (−2.3 to 0.6)0.23
Control132.4 (17.0)132.5 (17.1)
 DBP (mm Hg)Intervention81.3 (10.1)80.9 (10.1)−0.6 (−1.5 to 0.3)0.19
Control82.2 (10.4)82.4 (10.2)
 HbA1c (%)Intervention5.8 (0.4)5.8 (0.6)−0.02 (−0.07 to 0.02)0.35
Control5.7 (0.4)5.8 (0.5)
Inclusion based on HbA1c
 Weight (kg)Intervention76.2 (14.5)74.5 (14.7)−1.5 (−2.3 to −0.6)<0.001
Control75.4 (13.9)75.2 (14.5)
 Waist circumference (cm)Intervention100.4 (10.6)98.3 (11.1)−2.1 (−3.0 to −1.2)<0.001
Control100.6 (11.1)100.5 (11.0)
 SBP (mm Hg)Intervention130.3 (17.5)132.4 (18.2)−1.5 (−3.6 to 0.5)0.14
Control131.4 (17.2)130.1 (17.2)
 DBP (mm Hg)Intervention80.5 (10.4)79.7 (10.5)−1.6 (−2.8 to −0.4)0.009
Control80.6 (10.4)81.6 (10.9)
 HbA1c (%)Intervention6.2 (0.1)6.2 (0.7)−0.01 (−0.08 to 0.06)0.69
Control6.2 (0.1)6.2 (0.5)
  • Data are presented as mean and SD. Adjusted group differences are adjusted for stratification variables at randomisation (country and site), confounders (sex and age) and for corresponding baseline value.

  • DBP, diastolic blood pressure; HbA1c, haemoglobin A1c; SBP, systolic blood pressure.